Pulsenmore Builds U.S. Momentum with Another Commercial Engagement Following FDA Clearance

Core Viewpoint - Pulsenmore Ltd. has announced a new commercial engagement with TLC Perinatal PA to incorporate its home ultrasound technology into maternal-fetal care in the U.S. [1][2] Group 1: Company Overview - Pulsenmore Ltd. specializes in home ultrasound technology aimed at improving maternal health by connecting mothers and healthcare providers remotely [6]. - The company is focused on expanding access to prenatal care through innovative solutions that enhance patient-centric care [6]. Group 2: Partnership Details - The services agreement with TLC Perinatal PA allows patients to perform ultrasound scans at home as part of a hybrid care model that includes telehealth and in-clinic visits [2]. - TLC Perinatal manages approximately 2,000 pregnancies annually and is recognized for integrating new technologies into prenatal care [4]. Group 3: Industry Trends - There is a growing interest among U.S. maternal-fetal medicine practices in adopting technologies that extend care beyond traditional clinic settings [3]. - The integration of home ultrasound with telehealth is seen as a way to maintain clinical oversight while providing patients with greater flexibility and continuity of care [3]. Group 4: Expert Commentary - Dr. Richie Broth, Medical Director of TLC Perinatal, emphasized that Pulsenmore's Home Ultrasound enhances prenatal care access and aligns with ACOG's 2025 Clinical Consensus [5]. - Dr. Elazar Sonnenschein, CEO of Pulsenmore, noted strong engagement from practices prioritizing innovation and patient-centered care as they begin commercial operations in the U.S. [6].